Select Page

Research Articles

BREAKING NEWS: FDA Votes to Approve AMX0035 Treatment for ALS

In an amazing update for the ALS community, on September 29, 2022, the FDA voted to approve ALS drug AMX0035 for the treatment of ALS. This comes a year after Amylyx, a Massachusetts-based pharmaceutical company, submitted a New Drug Application (NDA) for AMX0035, a...
Read More

ALS Clinical Care and the Future of Research

On November 15 2021, ALS Texas was joined by Neurologists and Clinic Directors, Dr. Jeffrey Tramonte and Dr. Stanley Appel for a special panel discussion. During this exciting presentation, they discussed the growth of multidisciplinary care and where the momentum is...
Read More

New Research Update for Proposed ALS Drug Treatment — AMX0035

We’re excited to share another milestone in the search for better drug treatments for ALS. Amylyx announced today that the company will soon submit a New Drug Application (NDA) for AMX0035 to the FDA. The ALS Association has been closely following the development of...
Read More

Advancing Research: The HEALEY ALS Platform Trial

In 2020, the ALS Association, in partnership with Massachusetts General Hospital, launched an innovative approach to research, the HEALEY ALS Platform Trial. In most clinical trials, a single drug is tested, and participants cannot be enrolled in more than one trial...
Read More